Host country: United States
Years since PhD: A New Investigator is an NIH research grant applicant who may not yet have competed successfully for a substantial, NIH research grant.
Award: $275,000 for R21 phase, $250,000 for R33 phase
Award Duration (years):
Subjects: Please check the website
Additional comments: This announcement is intended to encourage early career chemists (or chemists new to NIH) to develop probes that aid basic research investigations on drug abuse and/or identify new or better templates as lead compounds with potential for conducting structure activity relationship (SAR)-function studies. Importantly, this includes the identification of new chemical entities (NCEs) with therapeutic potential for drug abuse and addiction. Applicants responding to this FOA should explain their rationale for the proposed work, the inclusion of pharmacologic assessments, and the relationship of the research proposed in the context of a broader medications development pipeline (e.g., Target Identification > Probe/ligand screening > Synthesis of ligands > Assay development > Proof of concept > Lead optimization, etc.). For example, a PD/PI who has previously received a competing NIH R01 research grant is no longer considered a New Investigator. However, a PD/PI who has received a small grant (R03) or an Exploratory, Developmental Research Grant Award (R21) retains his or her status as a New Investigator. For the R21 award, direct costs are limited to $250,000 over a two-year period, with a maximum of $200,000 allowed in any single year. The R33 award will be limited to $250,000 in direct costs per year.
How to apply? For further eligibility requirements and the application process, please visit: Official Funding website
This entry has been last updated: 2018-12-29 13:58:21